Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer

Completed · Not applicable

Conditions studied: Pancreatic Cancer

In brief

An early feasibility study to evaluate feasibility, radiotherapy benefits and safety when using TraceIT tissue spacer to create space between pancreas and duodenum in patients with localized Pancreatic Cancer.

Key facts

Study ID

NCT03998566

Run by

Boston Scientific Corporation

People needed

6

Starts

2019-04-24

Expected to finish

2021-05-01

Last updated by the study team

2023-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years old
• Biopsy-confirmed localized pancreatic cancer in the head or neck of the pancreas as defined by the NCCN guidelines
• Tumor is clearly delineable from duodenum and no clear evidence of invasion of the duodenum is seen at time of EUS performed for either diagnosis or fiducial placement.
• Subject is able to comply with motion management guidelines.
• Radiotherapy or chemoradiotherapy for treatment of the disease is indicated.
• In Investigator's opinion, medically fit to undergo endoscopy for fiducial marker implantation and TraceIT administration.
• Subjects Screening/Baseline laboratory testing must meet the following laboratory value criteria:
• White blood cell count: ≥ 3.0 x 109/L
• Absolute neutrophil count (ANC): ≥ 1.5 x 109/L
• Platelets: ≥ 100 x 109/L
• Total bilirubin: ≤ 2.0 times upper limit of normal (ULN)
• AST and ALT: ≤ 3.0 times institutional upper normal limit
• Serum creatinine: < 1.5 times ULN e
• INR: < 1.5
• Serum pregnancy: Negative
• Hemoglobin: ≥ 8.0 g/dl
• Zubrod Performance Status 0-2
• Subject or authorized representative, has been informed of the nature of the study and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) of the respective clinical site.
• Life expectancy of at least 9 months

You may not qualify if…

• Patients for whom radiotherapy is contraindicated
• Previous thoracic or abdominal radiotherapy
• Any GI abnormality that would interfere with the ability to access the injection site
• Presence of tumor invasion of the duodenum detected on EUS at time of biopsy
• Previous Whipple procedure or other resection of pancreatic tumor prior to screening
• Active gastroduodenal ulcer or uncontrolled watery diarrhea
• History of Chronic Renal Failure.
• Documented history of uncontrolled diabetes (i.e., symptomatic hyperglycemia that cannot be medically managed, fasting blood glucose level above 300 mg/dL, and/or frequent swings between hyperglycemia and hypoglycemia)
• Currently enrolled in another investigational drug or device trial that clinically interferes with this study.
• Unable to comply with the study requirements or follow-up schedule.
• Any condition or comorbidity that the Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the subject.
• Women who are pregnant or breast-feeding; women of child-bearing age must use contraceptives.

Where it is running

• Johns Hopkins Medicine — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.